Market revenue in 2023 | USD 617.2 million |
Market revenue in 2030 | USD 1,566.9 million |
Growth rate | 14.2% (CAGR from 2023 to 2030) |
Largest segment | Interferons |
Fastest growing segment | Growth Hormones |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Growth Hormones, Interferons, Vaccines, Immunostimulating Agents |
Key market players worldwide | Lonza Group Ltd, Catalent Inc, FUJIFILM Holdings Corp, WuXi Biologics (Cayman) Inc, Batavia Biosciences, Richter-Helm, Curia, HALIX, Biovian, Enzene Biosciences |
Interferons was the largest segment with a revenue share of 21.42% in 2023. Horizon Databook has segmented the Spain recombinant protein therapeutics cdmo market based on growth hormones, interferons, vaccines, immunostimulating agents covering the revenue growth of each sub-segment from 2018 to 2030.
For instance, according to Invest in Spain, Spain is one of Europe's principal markets, with 1,000+ companies wherein 500 of them are manufacturers. Moreover, several major companies choose the country as the destination for investment, not only to distribute products but to establish R&D, production, & service centers.
For instance, in December 2023, the Spanish CDMO Lean bio was set to invest an additional USD 22 million into a facility being constructed near Barcelona. The upcoming site is designed to accommodate three production lines capable of manufacturing recombinant proteins & antibodies, along with plasmid DNA and messenger RNA.
In addition, the high demand for medicines in the country due to the high burden of chronic diseases is promoting the demand for recombinant protein therapeutics CDMO in the country. A rise in the number of manufacturing facilities in the country is anticipated to fuel market growth. For instance, in March 2023, 3P Biopharmaceuticals (3P), a CDMO specializing in process development and cGMP manufacturing of biological products, began expanding its capabilities in protein production. This includes the installation of a new 500-liter stainless steel fermenter with fermentation technology, complementing its existing capacity for protein production from bacteria & yeast.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account